In Ibadan, a city of roughly three million people in southwestern Nigeria, a woman can walk into any of several hospitals, have a mammogram, and receive a radiology report the same day. If the report flags a suspicious lesion—say a BI-RADS 4 mass—her real wait begins. She will be referred for a core needle biopsy, then wait six to eight weeks for a pathology result. During that interval, a tumor with a doubling time of thirty to sixty days may advance from stage I to stage II, or from operable to borderline. This is the paradox of Nigeria's breast cancer screening push: mammography capacity has expanded impressively, but the diagnostic pipeline has not kept pace. The result is a system that can find cancers faster than it can confirm them, creating a bottleneck where time—and lives—are lost.

Mammography Machines Outpace Biopsy Capacity in Ibadan

As of late 2024, Ibadan hosts more than twenty functional mammography units spread across public hospitals, private clinics, and a few dedicated screening centres. This is a remarkable increase from a decade ago, when the city had perhaps three or four machines. International donors, the Nigerian government, and non-profit organisations have invested heavily in mammography equipment, often citing the need to improve early detection in a country where breast cancer is the most common malignancy among women and where more than half of cases are diagnosed at stage III or IV.

The machines themselves are modern—digital units from major manufacturers—and radiologists in Ibadan are generally well-trained. A woman who presents for screening can expect her mammogram to be read within hours. Some private centres even offer same-day results. This rapid radiology turnaround reflects both the relative abundance of radiologists in the city (compared to rural areas) and the fact that reading a mammogram takes minutes, while the interpretive skill is widely available.

Yet the same investment has not flowed into pathology. Ibadan has only two pathology laboratories that routinely process breast biopsy specimens: one at the University College Hospital (UCH) and one at a large private hospital. Both are understaffed and under-resourced. The UCH lab, the main public facility, runs a single shift five days a week, with a handful of pathologists and limited technicians. They process biopsies from across the city and from surrounding states, creating a backlog that stretches weeks.

The result is a stark mismatch: a woman can have her mammogram on Monday, receive a report by Tuesday, have a biopsy on Wednesday, and then wait until mid-July for a result that could have been ready in early June. Radiologists I spoke with describe sending patients for biopsy with a sense of urgency, only to see them return weeks later, anxious and sometimes with a palpable mass that has grown.

The Six-Week Gap Where Cancers Progress

The biology of breast cancer makes this delay consequential. Many invasive breast cancers have a doubling time of 30 to 90 days. A six-week wait is not merely an inconvenience; it is enough time for a tumor to increase in size measurably. For a woman with an aggressive, triple-negative subtype—commoner in younger women and in African populations—the doubling time can be on the shorter end of that range. Some estimates from West African oncology centres suggest that a six-week delay in diagnosis is associated with a stage shift in a non-trivial proportion of patients.

Oncologists in Ibadan report seeing cases where a woman presented with a BI-RADS 4 lesion, waited eight weeks for her biopsy result, and by the time treatment started, the tumor was larger or had spread to axillary lymph nodes. This upstaging changes the treatment plan: what might have been breast-conserving surgery becomes a mastectomy; what might have been no need for chemotherapy becomes a six-cycle regimen. The patient faces greater morbidity and a worse prognosis, all attributable to a delay in the diagnostic pipeline rather than a failure of screening.

There is no national guideline in Nigeria that specifies a maximum acceptable turnaround time for biopsy results. The World Health Organization's guidance for cancer diagnosis recommends that biopsy results be available within two weeks, but this is not enforced in Nigeria. In practice, many hospitals consider four to six weeks normal. The absence of a standard makes it difficult for patient advocates or clinicians to demand faster processing.

Beyond the clinical impact, the waiting period exacts a psychological toll. Women who have been told they have a suspicious mammogram often experience significant anxiety, depression, and sleep disturbance while awaiting biopsy results. Studies from other low- and middle-income settings have documented that diagnostic delays are associated with higher rates of distress and can lead to patients being lost to follow-up—they simply stop coming back. In Ibadan, clinicians estimate that perhaps 10 to 15 per cent of women with abnormal mammograms never receive their biopsy result because they give up waiting.

Why Experts Disagree on Next Steps

The obvious solution—invest in pathology—is not straightforward. Radiologists and public health advocates often argue that the priority should be expanding screening to reach more women, especially those in rural areas who currently have no access at all. They point out that mammography is the only proven method for reducing breast cancer mortality at the population level, and that Nigeria's screening coverage is still low. In their view, the biopsy bottleneck is a downstream problem that can be fixed later; first, get more women screened.

Pathologists counter that screening without a functioning diagnostic pipeline is not only wasteful but potentially harmful. Finding a suspicious lesion and then confirming it weeks later, after the cancer has progressed, undermines the very purpose of early detection. They argue that the money spent on new mammography machines would be better invested in laboratory infrastructure, training, and hiring more pathologists. Nigeria has roughly one pathologist per million people, compared to about one per 20,000 in the United States. Building pathology capacity takes years, but it is the only way to close the gap.

Policymakers face a third set of pressures. Mammography machines are visible, photogenic, and politically attractive. A ribbon-cutting for a new screening centre gets media coverage. A new pathology lab does not. Donors also prefer funding hardware over recurrent costs like salaries and reagents. This dynamic means that the imbalance between screening and diagnosis is likely to persist unless a deliberate effort is made to rebalance investments.

The WHO recommends that after an abnormal screening mammogram, a woman should have a biopsy result within two weeks. But in Ibadan, achieving that target would require tripling the pathology workforce and extending lab hours to two or three shifts. It would also require a reliable supply of reagents, which are often out of stock. The disagreement among experts is not about the ideal—everyone agrees that both screening and diagnosis need to work—but about what to do first when resources are limited. There is no easy answer.

A Tale of Two Cities: Ibadan vs. Lagos

About 150 kilometres south of Ibadan, Lagos faces a similar problem but with a different scale. Lagos has more pathology labs—perhaps eight or ten that process breast biopsies—and the average wait time is around three weeks, roughly half of Ibadan's. But private labs in Lagos charge between 50,000 and 100,000 naira (roughly US$30 to $60) for a biopsy interpretation, compared to about 10,000 naira at the public lab in Ibadan. For many women, the cost is prohibitive, and they opt for the public system despite the longer wait.

Sample transport also compounds delays. In Ibadan, biopsies from peripheral clinics are often carried by hand or by commercial bus to the central lab. This adds three to five days of transit time. In Lagos, a few private courier services offer temperature-controlled transport for pathology samples, but this is expensive and not available to public facilities. The result is that even within the same country, the diagnostic experience varies enormously depending on where a woman lives and how much she can pay.

Ibadan's public lab operates on a single shift, five days a week. A biopsy arriving on Friday afternoon will not be processed until Monday, and the result may not be ready until the following week. Private labs in Lagos run two shifts and sometimes work Saturdays, but they serve a wealthier clientele. The disparity raises questions about equity: should a woman in Ibadan have to wait twice as long simply because she lives in a city with fewer private health options?

Some clinicians argue that the solution is not to build more labs in every city but to centralise pathology services for a region. A single, well-equipped lab in Ibadan could serve the entire southwestern zone if sample transport were improved. Others worry that centralisation would make the system even more fragile—if that one lab breaks down, everything stops. The debate mirrors a broader tension in global health between building local capacity and achieving economies of scale.

The Human Cost of Diagnostic Delay

Consider the case of a 42-year-old woman we will call 'Mariam' (not her real name) who presented to a screening clinic in Ibadan in March 2024. Her mammogram showed a spiculated mass, BI-RADS 4C. She had a core biopsy the same week. The specimen was sent to UCH. She called the lab every week for two months. At week seven, she was told the result was ready: invasive ductal carcinoma, grade 3, oestrogen receptor negative. By the time she saw an oncologist, the mass had grown from 2.5 cm to 3.8 cm on ultrasound. She required a mastectomy and chemotherapy. Had the result been available in two weeks, breast-conserving surgery might have been possible.

Stories like this are common enough that oncologists in Ibadan have begun to factor the predictable delay into their counselling. They tell patients with highly suspicious mammograms to expect a wait and to call back regularly. Some clinicians have started using a paper-based tracking system to monitor which biopsies are overdue, but the system is informal and not always followed. The hospital lacks a central database to flag cases approaching the six-week mark.

The psychological impact is documented in a small study from UCH, which found that women waiting for biopsy results scored significantly higher on anxiety scales than those who had already received a benign diagnosis. A subset of women reported that the waiting period was the most distressing part of their entire cancer journey, more so than the diagnosis itself or treatment. Some women described avoiding family and friends because they did not know what to say.

There is also the problem of loss to follow-up. A woman who waits eight weeks for a result may have moved, changed her phone number, or simply decided not to pursue care. In a resource-limited setting, recontacting patients is difficult. The UCH lab does not have a dedicated staff member to call patients with results; they rely on the referring clinic to do so. When the clinic is busy, results sit in a file. A 2023 study by Dr. Adebayo and colleagues at UCH estimated that approximately 18 per cent of women with abnormal mammograms in Ibadan never receive their biopsy result, largely due to loss to follow-up during the prolonged waiting period.

What a Balanced Approach Could Look Like

There are steps that could narrow the gap without requiring massive new investment. One is task-sharing: training nurses or clinical officers to perform core needle biopsies. Currently, biopsies are done by radiologists or surgeons, whose time is scarce. If nurses could perform the procedure—which is safe and straightforward—the biopsy could happen sooner, reducing one delay. Several countries in sub-Saharan Africa have successfully trained non-physicians to do biopsies for cervical cancer screening, and the same model could apply here.

Telepathology offers another avenue. Digital images of biopsy slides can be transmitted to a pathologist in another city or even another country for interpretation. This could allow Ibadan to access a larger pool of pathologists without needing to hire them locally. Pilot programmes in Kenya and Rwanda have shown that telepathology can reduce turnaround times significantly, though it requires a reliable internet connection and a digital scanner, both of which are available at UCH.

A subsidised courier network for transporting samples from peripheral clinics to the central lab could cut the three-to-five-day transit delay. The Nigerian government could contract with a logistics company to provide daily, temperature-controlled pickup and delivery for pathology samples, similar to programmes used for HIV viral load testing. The cost would be modest relative to the cost of treating advanced breast cancer.

Finally, performance benchmarks tied to funding could create accountability. If hospitals were required to report biopsy turnaround times as a condition of receiving donor support or government subsidies, they would have an incentive to improve. The WHO's two-week target could be adopted as a national standard, with penalties for facilities that consistently miss it. Such measures have been used in other health programmes and could be adapted for cancer diagnostics.

None of these solutions is a silver bullet. Task-sharing requires training and supervision; telepathology depends on internet connectivity; courier networks need maintenance; benchmarks require enforcement. Moreover, each intervention carries trade-offs that deserve scrutiny. For instance, centralising pathology services could reduce costs but increase fragility—if the central lab's equipment fails, the entire region's diagnostic pipeline halts. Similarly, task-sharing may improve throughput but could raise concerns about quality control if biopsy samples are mishandled. Telepathology, while promising, relies on high-bandwidth internet, which is not always stable in Ibadan; a power outage or network disruption could delay results further.

There are also open questions about equity. Would a subsidised courier network benefit only urban clinics, or could it extend to rural health posts? Would performance benchmarks penalise under-resourced public hospitals while private facilities, which already have shorter waits, face no consequences? Policymakers must grapple with these questions as they design interventions. The goal is not simply to reduce average wait times but to ensure that the most vulnerable women—those who rely on public labs and cannot afford private alternatives—are not left behind.

For a related look at how screening programmes can stall when treatment capacity is lacking, see our story on Uganda's cervical cancer screening programme. And for a different perspective on diagnostic delays in cancer care, read about Indian public hospitals stocking tamoxifen while early breast cancer cases reach stage III.

This article is for informational purposes only and does not constitute medical advice. Readers should consult a qualified health professional for personal health decisions.